Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCAP: Gene Therapy + IMRT for Prostate Cancer
NCT00583492Phase 2Completed
- Sponsor
- Henry Ford Health
- Start
- Dec 2007
- Primary completion
- Sep 2013
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ad5-ycd/muttksr39rep-adp in prostate cancer (PCa), sponsored by Henry Ford Health. Primary endpoint: Freedom From Biochemical/Clinical Failure at 5 years. Started Dec 2007; status: completed.
02
Drugs
ad5-ycd/muttksr39rep-adp
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00583492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583492.